Navigation Links
BELLUS HEALTH reports results for first quarter of fiscal 2008
Date:5/5/2008

of Amyloid A (AA) amyloidosis. During the current quarter, the Company announced its decision to pursue the drug development program for eprodisate (KIACTA(TM)) and that it will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). The trial is expected to begin in the fourth quarter of 2008, with approximately 150 patients to be followed for a period of 24 months. As part of the decision, the Company withdrew its marketing applications for eprodisate (KIACTA(TM)) in the U.S., the European Union and Switzerland. On April 15, 2008, the Company announced that it had regained full ownership rights and control of eprodisate (KIACTA(TM)) from Centocor. The refundable portion ($6,000,000) of the upfront payment received from Centocor in 2005 has been classified in accrued liabilities as of March 31, 2008, given that it will be refunded to Centocor.

Reimbursable costs revenue amounted to $22,000 for the current quarter, compared to $128,000 for the same period the previous year, and consists of costs reimbursable by Centocor in respect of eprodisate (KIACTA(TM))-related activities. The Company earns no margin on these reimbursable costs.

Research and development expenses, before research tax credits and grants, amounted to $8,780,000 for the current quarter, compared to $16,828,000 for the same period the previous year. The decrease in the current quarter compared to the same period the previous year is mainly attributable to a reduction in expenses incurred in relation to the development of tramiprosate (ALZHEMED(TM); homotaurine) for the treatment of Alzheimer's disease (AD), following the Company's decision in November 2007 to terminate the tramiprosate (ALZHEMED(TM)) pharmaceutical drug development program. Leveraging the many years of accumulated knowledge and the experience it has gained in developing tramiprosate (ALZHEMED(TM
'/>"/>

SOURCE BELLUS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Air pollution linked to cardiovascular risk indices in healthy young adults
5. More proof needed of safety and quality of electronic personal health records
6. Health care incentive model offers collaborative approach
7. Loneliness is bad for your health
8. Mailman School of Public Health study examines link between racial discrimination and substance use
9. Green Tea May Brew Up Healthier Skin
10. For Health Info, Women Often Turn to the Web
11. Record Number of Americans Lack Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 SIMpalm, ... updated payment app for Forte Payment System. Forte Mobile ... ACH payments on iPhone, iPod and iPad. The ... been recently updated by SIMpalm. This update was for ... currently supported on iOS 4.3 and is available to ...
(Date:7/22/2014)... treatment and cardiovascular risk assessment state that men have ... cardiovascular disease or of having a heart attack or ... (based on age, smoking history, and cholesterol and blood ... and how aggressively to treat high cholesterol are examined ... , a peer-reviewed publication from Mary Ann Liebert, Inc., ...
(Date:7/22/2014)... July 22, 2014 The Beryl Institute ... third annual Institute Scholar Program. These offerings reinforce the ... patient experience in healthcare and the need for rigorous ... grant and scholar programs are intended to ... Value of focusing on the patient experience before, ...
(Date:7/22/2014)... NY (PRWEB) July 22, 2014 ... ( http://www.risperdallawsuitcenter.com/ ) in the Philadelphia ... to deny punitive damages in cases alleging the ... growth), Bernstein Liebhard LLP reports. In an Order ... denied a plaintiffs’ request to certify the matter ...
(Date:7/22/2014)... 22, 2014 The park is the ... Kendalltown Homeowners Association, Inc., made a recent ... community with the purchase of playground equipment from American ... in beautiful Miami Florida, and is a 475-unit community ... the surrounding landscape has created a tropical paradise with ...
Breaking Medicine News(10 mins):Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3
... cancer drugs had yesterday won the final draft of approval ... ,The National Institute for Health and Clinical Excellence ... the use of three types of aromatase inhibitors in postmenopausal ... drugs would act by reducing the risk of tumors spreading ...
... is for hiking and camping, but it brings with it ... In order to prevent such illnesses, researchers //are looking at ... tea and vitamins C and E in preventing infection by ... Infectious Disease, part of the National Institutes of Health, awarded ...
... The central government will send an advisory to all ... aerated soft drinks //after an independent report found heavy ... an advisory to all state governments to educate the ... aerated soft drinks," Health Minister Anbumani Ramadoss told reporters ...
... study to be published in the August 15 issue of ... The Heart Research Institute in Sydney have warned// that a ... of burger can be sufficient enough to cause heart attack. ... 18 and 40, the researchers were shocked to find that ...
... Chairman, Eddie Thompson, who was diagnosed with prostate cancer ... for the disease at Ninewells Hospital. ,In a ... behalf last night, details of his illness were released ... media about his health. ,The new ...
... out some alarming statistics regarding the HIV and AIDS status ... ,Dr. Sheela Basrur, Ontario's chief medical officer, said, ... living with HIV and AIDS has increased in part because ... the mortality rates have been reduced through the introduction of ...
Cached Medicine News:Health News:Antioxidants Could Halt Rocky Mountain Spotted Fever 2
(Date:7/22/2014)... Research and Markets has announced the addition ... Reagent, by Application - Global Forecast to 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals are pharmaceutical products isolated ... most important and widely used techniques for biopharmaceutical production. ... cell culture market in 2013. Growth in the biopharmaceutical ...
(Date:7/22/2014)... According to a new ... (Technology Types - Near infrared (NIR) spectroscopy, Raman spectroscopy and ... Size, Share, Growth, Trends and Forecast, 2013 - 2019," the ... is expected to grow at a CAGR of 7.4% from ... was the largest contributor to global process spectroscopy market ...
(Date:7/22/2014)... 2014 BiologicTx ® today announced their ... Kidney Paired Donation transplant exchange utilizing BiologicTx,s proprietary matching ... 9 at the Miami Transplant Institute, located at Jackson ... Kidney Paired Donation (KPD) is an ... kidney transplant with one another due to incompatible blood ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3
... July 12, 2011 Sevocity, the leader in ... v11.1 has achieved full certification through the Certification ... a CCHIT Certified® 2011 Ambulatory EHR.  Sevocity v11.1 ... the highest level awarded by CCHIT.  The Certification ...
... 12, 2011 ,   ... are,pleased to announce that they have been engaged ... apricitabine (ATC), a late-stage,novel treatment for HIV infection. ... the,healthcare and investment business sectors. Dr ...
Cached Medicine Technology:Sevocity Division of Conceptual MindWorks Inc.'s Sevocity EHR Earns CCHIT 2011 Certification 2PharmaVentures Engaged by Avexa to Assist in the Out-licensing of Apricitabine 2
... The Answer to Micro-Incision Cataract ... Technology With its unique double-step ... knife is ideal for MICS. ... reproducible incisions that allow you ...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Injection Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Medicine Products: